RxDoctor Payments Data

Vanessa Wall

Optometrist · Jonesboro, ARNPI 1417260019

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 27.2% of the total. Among optometrist clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,958in general payments, 2019–2025

Across 128 payments — averaging $30.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sight Sciences, Inc.$557
  • Biotissue Holdings Inc.$521
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$374
  • Mallinckrodt Hospital Products Inc.$297
  • Bausch & Lomb Americas Inc.$282
  • plus $850 from 17 others

What the payments were for

  • Food & beverage$3,85397%
  • Entertainment$1053%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,958 in reported general payments places this provider in the 95th percentile of 442 optometrist providers in Arkansas.

See all optometrist providers in Arkansas

Medicare billing

Part B allowed, 2024
$37,665
Medicare patients
264
Services billed
455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine14$22,260
Prednisolone Acetate36$1,385
ValacyclovirValacyclovir Hcl17$755
Latanoprost45$320
MoxifloxacinMoxifloxacin Hcl11$248
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat14$155
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha11$137
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim12$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$1,077$22,26014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 442 optometrist providers in Arkansas.

Other optometrist in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →